Designing for Success: Accelerating Patient Inclusion in Early-Phase Translational Medicine
- Practical strategies for successful IVD and CDx regulatory submissions and clinical studies
- How the EU IVDR Article 5(5) Health Institution Exemption can provide speed and flexibility for pharma-led precision medicine programmes
- Lessons learned and case studies from ARC’s collaborations in translational and precision medicine trials